Liquid Embolic Agent Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Ethylene Vinyl Alcohol Copolymer (EVOH), Cyanoacrylates, Others), By Application (Arteriovenous Malformations (AVM), Hypervascularity Tumors, Peripheral Vasculature Haemorrhage, Others), By Region and Competition, 2020-2030F

Market Overview

Global Liquid Embolic Agent Market was valued at USD 255.48 Million in 2024 and is expected to reach USD 366.13 Million by 2030 with a CAGR of 6.38%. Liquid embolic agents are specialized medical substances used to occlude (block) abnormal blood vessels or blood flow during interventional radiology procedures. These agents are typically used in the treatment of neurovascular and peripheral vascular diseases and are administered via catheters in image-guided settings. One of the primary factors contributing to market expansion is the global rise in vascular-related diseases, particularly in aging populations.

Additionally, the growing preference for minimally invasive surgical techniques is supporting market growth, as these procedures generally result in fewer complications, shorter hospital stays, and reduced overall healthcare costs. Despite these favorable trends, the market faces certain challenges. The high cost associated with embolization procedures and the embolic agents themselves can be a significant barrier, especially in low- and middle-income countries.

Key Market Drivers

Growth in Healthcare Industry

The ongoing expansion of the global healthcare industry serves as a significant catalyst for the growth of the liquid embolic agent market. The global healthcare industry generates annual sales exceeding USD 4 trillion. The most significant and profitable segments are pharmaceuticals and biotechnology, with revenues approaching USD 850 billion, followed by medical technology and diagnostics, which generate over USD 400 billion. As healthcare infrastructure improves and investment in advanced medical technologies increases worldwide, the demand for minimally invasive procedures particularly in the fields of interventional radiology and neurovascular treatment continues to rise.

Liquid embolic agents, which are critical in procedures such as the treatment of arteriovenous malformations (AVMs), aneurysms, and tumors, are benefiting directly from these trends. For instance, Onyx has proven to be a safe and effective option for the embolization of brain arteriovenous malformations (AVMs). It enables complete obliteration in smaller AVMs, while larger AVMs can be sufficiently reduced in size to facilitate subsequent surgical or radiosurgical intervention. The rising prevalence of chronic conditions, especially neurological and oncological disorders, has further heightened the need for targeted, safe, and effective embolization solutions.

Surge in Technological Advancements

The global liquid embolic agent market is experiencing significant growth, driven in large part by rapid technological advancements in interventional radiology and neurovascular therapies. Innovations in imaging technologies, catheter design, and embolic agent formulation have substantially enhanced the precision, efficacy, and safety of embolization procedures. These advancements are enabling healthcare professionals to treat complex vascular conditions, such as arteriovenous malformations (AVMs) and aneurysms, with greater confidence and improved patient outcomes.

Moreover, the integration of artificial intelligence (AI) and 3D imaging technologies is streamlining procedural planning and real-time navigation, reducing complication rates and procedural times. The development of next-generation liquid embolic agents with improved biocompatibility, controlled delivery, and longer shelf life is also expanding their application across a broader range of clinical indications. In July 2025, Arsenal Medical released late-breaking data from the EMBO-02 clinical trial evaluating NeoCast, a next-generation, shear-responsive liquid embolic therapy. The study assessed the use of NeoCast in patients with chronic subdural hematoma (cSDH), a condition involving blood accumulation on the brain’s surface, through middle meningeal artery embolization (MMAe).

Download Free Sample Report

Key Market Challenges

Need for Specialized Skills and Training

A significant challenge facing the global liquid embolic agent market is the critical need for specialized skills and comprehensive training among healthcare professionals. The administration of liquid embolic agents requires advanced technical expertise, as these procedures involve precise catheter navigation and controlled delivery of embolic materials within complex vascular structures. Ensuring procedural success and minimizing risks such as non-target embolization or vessel damage depend heavily on the proficiency of interventional radiologists, neurosurgeons, and related specialists.

However, there is a notable shortage of adequately trained personnel with the necessary experience and knowledge to perform these highly intricate procedures, particularly in emerging and underdeveloped regions. The lack of standardized training programs and limited access to hands-on learning opportunities further exacerbate this issue. This skills gap poses a barrier to the widespread adoption of liquid embolic agents, restricting their availability to select medical centers with specialized expertise.

Key Market Trends

Rising Prevalence of Oncology Conditions

The increasing incidence of oncology-related conditions worldwide is emerging as a prominent trend driving the growth of the global liquid embolic agent market. In 2022, there were approximately 20 million new cancer diagnoses and 9.7 million cancer-related deaths globally. The estimated number of individuals surviving at least five years post-diagnosis reached 53.5 million. Statistically, one in five people will develop cancer during their lifetime, with mortality rates of approximately one in nine for men and one in twelve for women.

With cancer cases on the rise due to factors such as aging populations, lifestyle changes, and environmental influences, there is a growing demand for innovative and minimally invasive treatment options. Liquid embolic agents play a critical role in oncological interventions, particularly in the targeted management of tumors through embolization techniques. These agents are used to selectively block blood flow to tumors, thereby inhibiting their growth and enhancing the effectiveness of adjunct therapies such as chemotherapy and radiation.

Segmental Insights

Product Type Insights

Based on Product Type, Ethylene Vinyl Alcohol Copolymer (EVOH) have emerged as the fastest growing segment in the Global Liquid Embolic Agent Market in 2024. This is due to its superior clinical performance and safety profile. EVOH-based embolic agents offer excellent radiopacity, enabling precise visualization during procedures, which is critical for targeting complex vascular abnormalities. Its unique non-adhesive properties minimize the risk of catheter entrapment and reduce procedural complications, enhancing overall procedural success rates.

Application Insights

Based on Application, Arteriovenous Malformations (AVM) have emerged as the fastest growing segment in the Global Liquid Embolic Agent Market during the forecast period. This is due to a combination of clinical, technological, and market dynamics. The rising prevalence of AVMs, coupled with advancements in diagnostic imaging, has significantly improved the identification and diagnosis of these vascular anomalies. This increased detection rate has driven demand for effective, minimally invasive treatment options, positioning liquid embolic agents as a preferred therapeutic solution.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Liquid Embolic Agent Market in 2024. This is due to a combination of advanced healthcare infrastructure, a robust research and development ecosystem, and the presence of leading market players. The region’s healthcare facilities are equipped with cutting-edge technology, which facilitates the widespread adoption of innovative liquid embolic agents. Additionally, substantial investments in R&D by both private companies and public institutions fuel continuous innovation, ensuring that North America remains at the forefront of product development in this field.

Recent Development

• In July 2025, IHT Medical announced the commencement of enrollment for the CLARITE pivotal trial, led by René Chapot at Alfried Krupp Krankenhaus, Essen, Germany. This study targets the endovascular treatment of arteriovenous pathologies utilizing the Obtura liquid embolic system. Obtura represents a next-generation liquid embolic agent with a proprietary, first-in-class radiopacity-loss mechanism, eliminating the need for shaking and delivering enhanced penetration. These distinctive features offer a novel approach to embolization procedures.
• In March 2024, CERENOVUS Inc., a leading innovator in neurovascular care and a subsidiary of Johnson & Johnson MedTech, announced the launch of the TRUFILL n-BCA Liquid Embolic System Procedural Set. This new addition to CERENOVUS’s hemorrhagic stroke portfolio offers the TRUFILL n-BCA Liquid Embolic System in a comprehensive procedural set, featuring two configurations along with all necessary accessories for preparation and delivery in a single sterilized package, thereby streamlining procedure setup. The TRUFILL n-BCA Liquid Embolic System is utilized under fluoroscopic guidance to obstruct or reduce blood flow to cerebral arteriovenous malformations (AVMs) through super-selective catheter delivery, primarily for pre-surgical devascularization.
• In August 2025, the Embrace Hydrogel Embolic System (HES), a polyethylene glycol (PEG)-based hydrogel embolic device, received US premarket approval for the embolization of hypervascular tumors in peripheral arteries, representing a major advancement in interventional oncology. This approval is particularly significant as it marks the first and only liquid embolic system authorized for this indication, supported by data from a prospective, randomized, controlled clinical trial. The system offers a novel therapeutic option for cancer patients with tumors exhibiting abnormal vascularization, which are often difficult to treat surgically due to elevated bleeding risks.
• In November 2024, iVascular announced the launch of Opal, the first-in-human clinical study evaluating Amber, a new embolic liquid formulated from a radiopaque biocompatible copolymer. Opal is a prospective, single-arm, multicenter trial involving 70 patients requiring peripheral embolization. Conducted in collaboration with 10 specialized embolization centers across Spain, the study will be led by Hospital La Fe in Valencia. The primary objective of the Opal study is to assess the safety and efficacy of Amber in treating vascular anomalies, hemorrhages, aneurysms, pseudoaneurysms, type II endoleaks, varicose veins, portal veins, hypervascular tumors, and pathological organs.

Key Market Players

• Johnson & Johnson Services, Inc.
• Medtronic Plc
• B. Braun SE
• Terumo Corporation
• Boston Scientific Corporation
• Balt
• Blacks wan Vascular, Inc.
• INVAMED
• Meril
• Gem srl

Report Scope

In this report, the Global Liquid Embolic Agent Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Liquid Embolic Agent Market, By Product Type:

o   Ethylene Vinyl Alcohol Copolymer (EVOH)

o   Cyanoacrylates

o   Others

• Liquid Embolic Agent Market, By Application:

o   Arteriovenous Malformations (AVM)

o   Hypervascularity Tumors

o   Peripheral Vasculature Haemorrhage

o   Others

• Liquid Embolic Agent Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Liquid Embolic Agent Market.

Available Customizations:

Global Liquid Embolic Agent Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Liquid Embolic Agent Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]